Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Itraconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP8B1 | Q9UNU6 | 2/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 1/20 | 1.00 |
| ▸ | TACR1 | P25103 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | CCR4 | P51679 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itraconazole SCHEMBL14875797 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL16984893 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL14875705 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL18073409 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL23934 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL15948108 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL18241650 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL20464865 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL14875903 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN | |
| Itraconazole SCHEMBL64913 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2LMNACYP51A1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 577 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3813799-B1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-02-21 | — | — | EP | claimed |
| CN-116925052-A | Synthesis method of optically pure itraconazole | 上海现代哈森（商丘）药业有限公司 | 2023-10-24 | — | — | CN | claimed |
| US-20230158259-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS | TOPELIA AUST LIMITED (652 771 670) (AU) | 2023-05-25 | — | — | US | claimed |
| CN-115955965-A | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | 拓比利亚欧斯特有限公司 | 2023-04-11 | — | — | CN | claimed |
| EP-4138832-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS | Topelia Aust Limited (AU) | 2023-03-01 | — | — | EP | claimed |
| US-20220401579-A1 | INCLUSION COMPLEXES OF PHARMACEUTICALS AND CYCLIC OLIGOMERS | DISPERSOL TECHNOLOGIES, LLC (US) | 2022-12-22 | — | — | US | claimed |
| US-20220378861-A1 | COMPOSITIONS AND METHODS FOR DELIVERING CANNABINOIDS USING MICRONEEDLE DEVICES TO THE SKIN | AQUAVIT PHARMACEUTICALS INC (US) | 2022-12-01 | — | — | US | claimed |
| CN-115219611-A | Kit for determining 7 antifungal drugs in serum by ultra-high performance liquid chromatography-tandem mass spectrometry and application thereof | 上海义准生物有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-114660200-A | Method for simultaneously measuring 4 triazole antifungal drugs in blood plasma by high performance liquid chromatography tandem mass spectrometry technology | 中国人民解放军总医院 | 2022-06-24 | — | — | CN | claimed |
| EP-3753966-B1 | AMPHIPHILIC BLOCK COPOLYMER, PREPARATION METHOD THEREOF AND NANOMICELLE DRUG-LOADING SYSTEM | SHANGHAI BEST LINK BIOSCIENCE LLC (CN) | 2022-05-25 | — | — | EP | claimed |
| US-20220143143-A1 | USE OF ACTIVATORS OF THE ARYL HYDROCARBON RECEPTOR FOR TREATING GLUTEN-INDUCED GASTROINTESTINAL DISEASES | UNIV MCMASTER (CA) | 2022-05-12 | — | — | US | claimed |
| WO-2022094174-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESOPHAGEAL CONDITIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| EP-1511490-A4 | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | TRANSFORM PHARMACEUTICALS INC (US) | 2009-03-11 | — | — | EP | claimed |
| US-20080305173-A1 | AMORPHOUS DRUG BEADS | BOGUE BEUFORD ARLIE | 2008-12-11 | — | — | US | claimed |
| EP-1511490-A2 | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | Transform Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| WO-2004108114-A2 | ANTI-FUNGAL COMPOSITION AND A PROCESS FOR ITS MANUFACTURE | PATEL DINESH SHANTILAL (IN) | 2004-12-16 | — | — | WO | claimed |
| WO-2003101392-A2 | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | claimed |
| US-20030026843-A1 | Amorphous drug beads | CAPRICORN PHARMA INC. | 2003-02-06 | — | — | US | claimed |
| US-4988697-A | Alpha-demethylase inhibiting azole compound and a beta-lactone | MERCK & CO., INC. (US) | 1991-01-29 | — | — | US | claimed |
| CN-122031617-A | Traditional Chinese medicine composition and traditional Chinese medicine preparation for preventing and treating invasive aspergillosis as well as preparation method and application of traditional Chinese medicine composition and traditional Chinese medicine preparation | 淮北市中医医院 | 2026-05-15 | — | — | CN | disclosed |
| US-20260102391-A1 | INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | LORICO AURELIO (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12582717-B2 | Protein based excipient for active pharmaceutical ingredients | DISPERSOME IP APS (NL) | 2026-03-24 | — | — | US | disclosed |
| US-20260076977-A1 | METHODS FOR TREATMENT OF DISEASES | GALERA LABS LLC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709721-A1 | DUAL EZH2-HSP90 INHIBITORS | Taipei Medical University (TW) | 2026-03-18 | — | — | EP | disclosed |
| US-12569482-B2 | Methods and compositions for treating idiopathic pulmonary fibrosis | LIANG GUI BAI (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260066250-A1 | METHOD AND DEVICE FOR THE QUANTIFICATION OF TARGET ION SPECIES | BRUKER DALTONICS GMBH & CO KG (DE) | 2026-03-05 | — | — | US | disclosed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | disclosed |
| US-20260047266-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20260041734-A1 | M-CSF FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL INFECTIONS IN STATES OF IMMUNOSUPPRESSION | UNIV DRESDEN TECH (DE) | 2026-02-12 | — | — | US | disclosed |
| US-12527789-B2 | Inhibition of a tripartite VOR protein complex in multicellular organisms | LORICO, Aurelio (US) | 2026-01-20 | — | — | US | disclosed |
| US-12508248-B2 | Therapeutic agent for prototheca disease | SEREN PHARMACEUTICALS INC. (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20250387326-A1 | CRYSTALLINE PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING SUGAR AND LIPID COMPOSITE PARTICLES AND PROCESS FOR MANUFACTURE | HOVIONE SCIENTIA LTD (IE) | 2025-12-25 | — | — | US | disclosed |
| US-12494355-B2 | Method and device for the quantification of target ion species | BRUKER DALTONICS GMBH & CO KG (DE) | 2025-12-09 | — | — | US | disclosed |
| EP-4651898-A1 | STABILIZED BIOPOLYMER COMPOSITION, THEIR MANUFACTURE AND USE | BASF SE (DE) | 2025-11-26 | — | — | EP | disclosed |
| CN-121005819-A | Biocompatible antibacterial composite material and preparation method thereof | 中国科学院化学研究所 | 2025-11-25 | — | — | CN | disclosed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| EP-4641223-A1 | SYSTEM FOR DETECTING LEAKAGE CURRENTS FOR DRIVE SYSTEMS OF VEHICLES WITH AN ELECTRIC DRIVE SYSTEM | CAF Power & Automation, S.L.U. (ES) | 2025-10-29 | — | — | EP | disclosed |
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-10-23 | — | — | US | disclosed |
| US-12435067-B2 | Truncated itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-10-07 | — | — | US | disclosed |
| US-12419838-B2 | Pharmaceutical formulation with improved solubility and bioavailability | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2025-09-23 | — | — | US | disclosed |
| EP-3522902-B1 | PROBIOTIC BACTERIA PRODUCING AN AHR AGONIST AND THEIR USE IN THE TREATMENT OF METABOLIC SYNDROME AND OBESITY | INSTITUT NATIONAL DE RECH POUR LAGRICULTURE LALIMENTATION ET LENVIRONNEMENT (FR) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608437-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608455-A1 | SELF-ASSEMBLING NANOPARTICLES | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250248986-A1 | ANTIFUNGAL DRUG INHALATION FORMULATIONS | Hefei Cosource Pharmaceuticals Co., Ltd (CN) | 2025-08-07 | — | — | US | disclosed |
| US-20250243176-A1 | (S)-1-(1-ACRYLOYLPIPERIDIN-3-YL)-2-FLUORO-5,6,7,8,9,10-HEXAHYDROCYCLO HEPTA[B]INDOLE-4-CARBOXAMIDE, AND RELATED CRYSTALLINE FORMS, COMPOSITIONS, AND METHODS THEREOF | VIDYA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-07-31 | — | — | US | disclosed |
| EP-4592677-A1 | METHOD FOR ASSISTING IN DETERMINING TREATMENT PLAN FOR DOG HAVING SKIN CONDITION | Nippon Zenyaku Kogyo Co., Ltd. (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-20250235422-A1 | DODECA-2,4,6,8,10-PENTAENOIC ACID COMPOSITIONS AND USES THEREOF | BIOMEDIT, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250228788-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250188013-A1 | LIPID COMPOUND AND USE THEREOF | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| EP-4558161-A1 | M-CSF FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL INFECTIONS IN STATES OF IMMUNOSUPPRESSION | Technische Universität Dresden (DE) | 2025-05-28 | — | — | EP | disclosed |
| US-20250161386-A1 | METHOD OF IMPROVING COGNITIVE FUNCTION IN ADULTS | SEMPERA ORGANICS, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-119950465-A | Application of carbonyl cyanide-4-trifluoromethoxy phenylhydrazone in aspergillus fumigatus infection prevention and treatment | 安徽中医药大学 | 2025-05-09 | — | — | CN | disclosed |
| US-12290538-B2 | Methods and products for treatment of gastrointestinal disorders | FINCH THERAPEUTICS HOLDINGS LLC (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4545147-A2 | PHOTOPROTECTIVE COMPOSITIONS CONTAINING MALASSEZIA-DERIVED COMPOUNDS AND/OR CHEMICAL ANALOGS THEREOF | VERSICOLOR TECHNOLOGIES, LLC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12285522-B2 | Thermally gelling drug formulations | UNM RAINFOREST INNOVATIONS (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250127717-A1 | COMPOSITIONS AND METHODS OF MAKING BRITTLE-MATRIX PARTICLES THROUGH BLISTER PACK FREEZING | UNIV TEXAS (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4539821-A1 | CRYSTALLINE PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING SUGAR AND LIPID COMPOSITE PARTICLES AND PROCESS FOR MANUFACTURE | Hovione Scientia Limited (IE) | 2025-04-23 | — | — | EP | disclosed |
| CN-119856599-A | Organic electroluminescent element | 日铁化学材料株式会社 | 2025-04-18 | — | — | CN | disclosed |
| CN-119798484-A | Retinoyl hyaluronic acid sodium acid and composition thereof | 山东省药学科学院 | 2025-04-11 | — | — | CN | disclosed |
| US-12263243-B2 | Templated open flocs of anisotropic particles for enhanced pulmonary delivery | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2025043394-A1 | KIT FOR FORMING SUPRAMOLECULAR SELF-ASSEMBLY COMPLEX AND USE THEREOF | 北京睿创康泰医药研究院有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-112996519-B | Compositions and methods for organ-specific delivery of nucleic acids | 德克萨斯大学系统董事会 | 2025-02-28 | — | — | CN | disclosed |
| US-20250060358-A1 | DIAGNOSIS AND TREATMENT OF HISTOPLASMOSIS | THE BRIGHAM AND WOMEN’S HOSPITAL INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12226404-B2 | Methods for making compositions for pulmonary administration | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250051519-A1 | SOLUTION ELECTROSPUN FIBERS, COMPOSITIONS COMPRISING THE SAME AND A PROCESS OF MANUFACTURING THEREOF | UNIVERSITEIT GENT (BE) | 2025-02-13 | — | — | US | disclosed |
| CN-119421870-A | Lipid compound and application thereof | 传信生物医药(苏州)有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119384273-A | Organ-specific delivery compositions for nucleic acids | 传信生物医药(苏州)有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-12203124-B2 | Methods for improved rapid antimicrobial susceptibility testing | SeLux Diagnostics, Inc. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20250017944-A1 | METHODS FOR TREATMENT OF DISEASES | GALERA LABS, LLC | 2025-01-16 | — | — | US | disclosed |
| US-20250000800-A1 | METHODS OF PREPARING DOSAGE FORMS USING 3D PRINTING CONTAINING AMORPHOUS SOLID DISPERSIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-01-02 | — | — | US | disclosed |
| EP-3774811-B1 | PHOTOPROTECTIVE COMPOSITIONS CONTAINING MALASSEZIA-DERIVED COMPOUNDS AND/OR CHEMICAL ANALOGS THEREOF | VERSICOLOR TECH LLC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240398760-A1 | CHELATED, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | SOMERSET THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| WO-2024249959-A1 | COMPOSITIONS REDUCING THE EXPRESSION OR ACTIVITY OF C1 GALT1 FOR TREATING EWING SARCOMA | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240390271-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240390272-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| CN-116064571-B | Mango salt-tolerant gene and identification method and application thereof | 中国热带农业科学院三亚研究院 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024238381-A1 | DUAL EZH2-HSP90 INHIBITORS | TAIPEI MEDICAL UNIVERSITY (TW) | 2024-11-21 | — | — | WO | disclosed |
| US-20240374512-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240374513-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240374511-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240374514-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-3998109-B1 | NOVEL THERAPEUTIC AGENT FOR PROTOTHECA DISEASE | SEREN PHARMACEUTICALS INC (JP) | 2024-11-13 | — | — | EP | disclosed |
| EP-3152321-B1 | DIAGNOSIS AND TREATMENT OF INVASIVE ASPERGILLOSIS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-118903162-A | Application of forsythoside A in preparation of medicines and method for screening active components in medicines | 闽江学院 | 2024-11-08 | — | — | CN | disclosed |
| CN-115845069-B | Combined medicine, application and kit for treating oral squamous cell carcinoma | 四川大学 | 2024-11-08 | — | — | CN | disclosed |
| EP-4456921-A2 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12133924-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240358718-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS | CORCEPT THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-3880702-B1 | METHOD AND KIT FOR THE DIAGNOSIS AND/OR PROGNOSIS OF INFLAMMATORY CONDITIONS | FUNDACIO INST DINVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL (ES) | 2024-10-30 | — | — | EP | disclosed |
| EP-4453292-A1 | SOLUTION ELECTROSPUN FIBERS, COMPOSITIONS COMPRISING THE SAME AND A PROCESS OF MANUFACTURING THEREOF | Universiteit Gent (BE) | 2024-10-30 | — | — | EP | disclosed |
| CN-116077499-B | Anti-azole aspergillus fumigatus pharmaceutical composition and application thereof | 徐州医科大学 | 2024-10-29 | — | — | CN | disclosed |
| US-12121512-B2 | Anti-fungal agent | SEREN PHARMACEUTICALS INC. (JP) | 2024-10-22 | — | — | US | disclosed |
| US-12121610-B2 | Compositions and methods for targeted delivery to cells | RECODE THERAPEUTICS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2024216136-A1 | COMBINATION THERAPY FOR THE TREATMENT OF HEMATOLOGICAL CANCERS | FOGHORN THERAPEUTICS INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024216151-A1 | COMBINATION THERAPY FOR TREATING HEMATOLOGICAL CANCERS | FOGHORN THERAPEUTICS INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-12102632-B2 | Quinolone dispersions | SOMERSET THERAPEUTICS, LLC (US) | 2024-10-01 | — | — | US | disclosed |
| US-12097210-B2 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | CORCEPT THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| CN-118660721-A | Compositions and methods for targeted delivery to cells | 德克萨斯大学系统董事会 | 2024-09-17 | — | — | CN | disclosed |
| US-20240301498-A1 | DIAGNOSTIC METHOD FOR CANCER EVOLUTION PREDICTION, AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-09-12 | — | — | US | disclosed |
| US-20240293351-A1 | METHODS OF ADMINISTERING SYNTHETIC TRITERPENOIDS | Reata Pharmaceuticals Holdings, LLC (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024177494-A1 | SYSTEM FOR SECURING PHOTOVOLTAIC MODULES TO TRAPEZOIDAL SHEET ROOFS | SANTANA CISNEROS ARTURO JAVIER (MX) | 2024-08-29 | — | — | WO | disclosed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-12071430-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240269269-A1 | Self-Assembling Nanoparticles | VACCITECH NORTH AMERICA, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240272140-A1 | DIAGNOSIS AND TREATMENT OF FUSARIOSIS AND SCEDOSPORIOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-3626242-B1 | ITRACONAZOLE ANALOGS AS INHIBITORS OF FIBROSIS | SCRIPPS RESEARCH INST (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-3641822-B1 | DRY-BINDERS FOR TABLETS BASED ON POLYETHYLENE GLYCOL-POLYVINYL ALCOHOL GRAFT POLYMERS, THE PRODUCTION AND USE THEREOF | BASF SE (DE) | 2024-08-07 | — | — | EP | disclosed |
| US-20240255506-A1 | PAIRED-CELL PROFILING SYSTEMS FOR HIGH-THROUGHPUT SCREENING SYNCYTIUM FORMATION | VERSITECH LIMITED (CN) | 2024-08-01 | — | — | US | disclosed |
| US-20240252449-A1 | STABILISED COMPOSITIONS | Rumin8 Pty Ltd (AU) | 2024-08-01 | — | — | US | disclosed |
| CN-118406679-A | Paired cell assay system for high throughput screening syncytia formation | 港大科桥有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118401506-A | (S) -1- (1-propenylpiperidin-3-yl) -2-fluoro-5, 6,7,8,9, 10-hexahydrocyclohepta [ b ] indole-4-carboxamide and related crystalline forms, compositions and methods | GB005股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240245618-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024153789-A1 | STABILIZED BIOPOLYMER COMPOSITION, THEIR MANUFACTURE AND USE | BASF SE (DE) | 2024-07-25 | — | — | WO | disclosed |
| US-20240245620-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4402278-A1 | DIAGNOSIS AND TREATMENT OF HISTOPLASMOSIS | The Brigham & Women's Hospital, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2024151838-A1 | CO-CRYSTALS WITH THIN-FILM FREEZE-DRYING PROCESS TO ENHANCE DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4400491-A1 | NOVEL LIPIDS USED FOR NUCLEIC ACID DELIVERY AND LIPID NANOPARTICLE COMPOSITION | Themedium Therapeutics Co., Ltd (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-3968964-B1 | METHOD FOR PRODUCING NANOPARTICLES | LEON NANODRUGS GMBH (DE) | 2024-07-10 | — | — | EP | disclosed |
| US-12029816-B2 | Compositions and methods of making brittle-matrix particles through blister pack freezing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029729-B2 | Chelated, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof | SOMERSET THERAPEUTICS, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| WO-2024141952-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | NOVOCURE GMBH (CH) | 2024-07-04 | — | — | WO | disclosed |
| US-20240216403-A1 | METHODS AND COMPOSITIONS FOR INHIBITING FIBROBLAST ACTIVATION | BIOPHARMA CREDIT PLC (GB) | 2024-07-04 | — | — | US | disclosed |
| EP-4393511-A1 | LIPID COMPOUND AND USE THEREOF | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393484-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393513-A1 | DRY SUSPENSION PARTICLES FOR DRY SUSPENSION, PREPARATION METHOD THEREFOR AND USE THEREOF | Livzon Pharmaceutical Group Inc. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-12023343-B2 | Thermo-kinetic mixing for pharmaceutical applications | AustinPx, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024133992-A1 | SYSTEM FOR DETECTING LEAKAGE CURRENTS FOR DRIVE SYSTEMS OF VEHICLES WITH AN ELECTRIC DRIVE SYSTEM | CAF POWER & AUTOMATION, S.L.U. (ES) | 2024-06-27 | — | — | WO | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| WO-2024136219-A1 | INHALATION FORMULATION COMPRISING NANOPARTICLES AND PREPARATION METHOD THEREFOR | 주식회사 포스테라헬스사이언스 | 2024-06-27 | — | — | WO | disclosed |
| US-12016855-B2 | Prednisolone and moxifloxacin compositions and methods | SOMERSET THERAPEUTICS, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240201166-A1 | DIAGNOSIS AND TREATMENT OF CONGESTIVE COLON FAILURE (CCF) | KHURANA VIKAS (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240197641-A1 | COMPOSITIONS AND METHODS FOR TARGETED SYSTEMIC DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-20 | — | — | US | disclosed |
| US-20240189239-A1 | PROCESS FOR CONTINUOUS HOT MELT GRANULATION OF LOW SOLUBLE PHARMACEUTICALS | MERCK PATENT GMBH (DE) | 2024-06-13 | — | — | US | disclosed |
| EP-3322814-B1 | METHOD FOR DETERMINING THE DEGREE OF SENSITIVITY OF A STRAIN OF FUNGUS TO AN ANTIFUNGAL AGENT | UNIV GRENOBLE ALPES (FR) | 2024-06-12 | — | — | EP | disclosed |
| EP-4380553-A1 | STABILISED COMPOSITIONS | Rumin8 Pty Ltd (AU) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024109794-A1 | NOVEL LIPIDS USED FOR NUCLEIC ACID DELIVERY AND LIPID NANOPARTICLE COMPOSITION | 传信生物医药(苏州)有限公司 | 2024-05-30 | — | — | WO | disclosed |
| EP-3954370-B1 | ANTI-FUNGAL AGENT | SEREN PHARMACEUTICALS INC (JP) | 2024-05-29 | — | — | EP | disclosed |
| US-11994510-B2 | Diagnosis and treatment of Fusariosis and Scedosporiosis | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-118103059-A | Self-assembled nanoparticles based on amphiphilic peptides | 巴林萨斯生物疗法北美公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240156920-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | STANDARD OF CARE CORPORATION | 2024-05-16 | — | — | US | disclosed |
| US-20240148666-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024092030-A1 | SELF-ASSEMBLING NANOPARTICLES | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024092028-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11969435-B2 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | CORCEPT THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| CN-115381797-B | Preparation and application of itraconazole sustained-release microspheres | 江南大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-117843659-A | Rapamycin analogues and uses thereof | 詹森药业有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117835967-A | Compositions and methods for targeted delivery to cells | 瑞科德治疗公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20240108639-A1 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-04-04 | — | — | US | disclosed |
| US-20240110192-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240108684-A1 | DOSING REGIMENS FOR TREATMENT OF FUNGAL INFECTIONS | NAPP PHARMACEUTICAL GROUP LIMITED (GB) | 2024-04-04 | — | — | US | disclosed |
| CN-117750948-A | Compositions and methods for targeted systemic delivery to cells | 瑞科德治疗公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024048537-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | 日鉄ケミカル＆マテリアル株式会社 | 2024-03-07 | — | — | WO | disclosed |
| US-20240076689-A1 | VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-03-07 | — | — | US | disclosed |
| CN-117643590-A | Combined medicine composition for treating candida infection and application thereof | 宁夏大学 | 2024-03-05 | — | — | CN | disclosed |
| US-20240058350-A1 | Methods of Treatment | ARENA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-3813799-B1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-02-21 | — | — | EP | disclosed |
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11896627-B2 | Bacteria engineered to treat metabolic diseases | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4312990-A1 | PROCESS FOR CONTINUOUS HOT MELT GRANULATION OF LOW SOLUBLE PHARMACEUTICALS | Merck Patent GmbH (DE) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313004-A1 | COMPOSITIONS AND METHODS FOR TARGETED SYSTEMIC DELIVERY TO CELLS | Recode Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313001-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4312987-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | Recode Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024026412-A1 | THIN FILM FREEZING METHODS AND COMPOSITIONS FORMULATED FROM DISPERSED ACTIVE AGENTS | TFF PHARMACEUTICALS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11883382-B2 | Buffer-free ophthalmological compositions of ketorolac and phenylephrine and applications thereof | SOMERSET THERAPEUTICS, LLC (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2024017998-A1 | M-CSF FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL INFECTIONS IN STATES OF IMMUNOSUPPRESSION | Technische Universität Dresden (DE) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020592-A1 | COSMETIC OR PERSONAL CARE COMPOSITION COMPRISING RECOMBINANT MILK PROTEIN | Perfect Day, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4309666-A1 | M-CSF FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL INFECTIONS IN STATES OF IMMUNOSUPPRESSION | Technische Universität Dresden (DE) | 2024-01-24 | — | — | EP | disclosed |
| CN-114668849-B | Shh pathway for modulating biological rhythms and related applications thereof | 中国人民解放军军事科学院军事医学研究院 | 2024-01-23 | — | — | CN | disclosed |
| WO-2024012270-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | 传信生物医药(苏州)有限公司 | 2024-01-18 | — | — | WO | disclosed |
| EP-4304562-A1 | METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING | Board of Regents, The University of Texas System (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11858917-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| CN-114126609-B | Novel therapeutic agent for prototheca | 株式会社赛轮制药 | 2024-01-02 | — | — | CN | disclosed |
| US-20230414635-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS | CORCEPT THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023247952-A1 | CRYSTALLINE PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING SUGAR AND LIPID COMPOSITE PARTICLES AND PROCESS FOR MANUFACTURE | HOVIONE SCIENTIA LIMITED (IE) | 2023-12-28 | — | — | WO | disclosed |
| US-20230414671-A1 | METHODS AND COMPOSITIONS FOR STEM CELL TRANSPLANTATION | ANGIOCRINE BIOSCIENCE INC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4294431-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | Vaccitech North America, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11850249-B2 | Methods of efficiently reducing intraocular pressure | SOMERSET THERAPEUTICS, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| CN-117241786-A | Method for preparing dry powder by using film freezing based on suspension | 德克萨斯大学系统董事会 | 2023-12-15 | — | — | CN | disclosed |
| US-20230398222-A1 | METHOD FOR PRODUCING AN AMORPHOUSE SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION FOR STABILIZING ACTIVE PHARMACEUTICAL INGREDIENTS | MERCK PATENT GMBH (DE) | 2023-12-14 | — | — | US | disclosed |
| US-20230390204-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR ENHANCING SOLUBILITY OF POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | MERCK PATENT GMBH (DE) | 2023-12-07 | — | — | US | disclosed |
| US-11826373-B2 | Methods for treatment of diseases | GALERA LABS, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| CN-117120036-A | Continuous hot melt granulation process for low-solubility pharmaceutical | 默克专利股份公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-4279071-A2 | NOVEL CANNABINOID FORMULATIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2023-11-22 | — | — | EP | disclosed |
| CN-117070374-A | Construction method of aspergillus fumigatus in-vitro bone invasion model | 荆州市中心医院(长江大学附属荆州医院) | 2023-11-17 | — | — | CN | disclosed |
| EP-4271375-A1 | METHODS OF TREATMENT | Arena Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4268896-A2 | DOSING REGIMENS FOR TREATMENT OF FUNGAL INFECTIONS | Cidara Therapeutics, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230338300-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-10-26 | — | — | US | disclosed |
| US-20230338411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11793789-B2 | Treatment of ophthalmological conditions using buffer-free ophthalmological compositions of ketorolac and phenylephrine | SOMERSET THERAPEUTICS, LLC (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116925052-A | Synthesis method of optically pure itraconazole | 上海现代哈森（商丘）药业有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116925052-A | Synthesis method of optically pure itraconazole | 上海现代哈森（商丘）药业有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4259143-A1 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | Board of Regents, The University of Texas System (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-4259829-A1 | DIAGNOSTIC METHOD FOR CANCER EVOLUTION PREDICTION, AND USES THEREOF | Institut National de la Santé et de la Recherche Médicale (FR) | 2023-10-18 | — | — | EP | disclosed |
| CN-116870166-A | Shh pathway for modulating biological rhythms and related applications thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-10-13 | — | — | CN | disclosed |
| EP-3368014-B1 | NOVEL CANNABINOID FORMULATIONS | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2023-10-04 | — | — | EP | disclosed |
| US-20230302138-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11766408-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| US-20230295277-A1 | UNIVERSAL CAR-NK CELL TARGETING VARIOUS EPITOPES OF HIV-1 GP160 | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-09-21 | — | — | US | disclosed |
| CN-110662756-B | Dimer-avoiding multiplex polymerase chain reaction for multi-target amplification | 艾瑞普特公司 | 2023-09-15 | — | — | CN | disclosed |
| EP-4236919-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR ENHANCING SOLUBILITY OF POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | Merck Patent GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-4236920-A1 | METHOD FOR PRODUCING AN AMORPHOUS SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION FOR STABILIZING ACTIVE PHARMACEUTICAL INGREDIENTS | Merck Patent GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| US-11737981-B2 | Cellulosic polymer nanoparticles and methods of forming them | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230619-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230619-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2023-08-23 | — | — | EP | disclosed |
| CN-116617150-A | Antifungal microneedle patch and preparation method and application thereof | 中山大学·深圳 | 2023-08-22 | — | — | CN | disclosed |
| US-11712459-B2 | Dosing regimens for treatment of fungal infections | CIDARA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3831839-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-07-26 | — | — | EP | disclosed |
| CN-113637603-B | Lactobacillus entericus and application thereof | 南京大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-115463218-B | Shh pathway for modulating biological rhythms and related applications thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-07-14 | — | — | CN | disclosed |
| US-20230219936-A1 | PROCESS FOR THE PREPARATION SALTS OF TRIAZOLE COMPOUNDS | CELLIX BIO PRIVATE LIMITED (IN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219936-A1 | PROCESS FOR THE PREPARATION SALTS OF TRIAZOLE COMPOUNDS | CELLIX BIO PRIVATE LIMITED (IN) | 2023-07-13 | — | — | US | disclosed |
| US-20230218533-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-13 | — | — | US | disclosed |
| US-11696910-B2 | Buffer-free, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof | SOMERSET THERAPEUTICS, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| CN-116406257-A | Pharmaceutical compositions and methods for increasing the solubility of poorly soluble active pharmaceutical ingredients | 默克专利股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023129915-A2 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-06 | — | — | WO | disclosed |
| CN-116390717-A | Method for preparing amorphous solid dispersions and pharmaceutical compositions for stabilizing active pharmaceutical ingredients | 默克专利股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116376937-A | Aspergillus fumigatus monocarboxylic acid transporter MFSmt gene and application thereof | 荆州市中心医院(长江大学附属荆州医院) | 2023-07-04 | — | — | CN | disclosed |
| US-11692212-B2 | Diagnosis and treatment of invasive aspergillosis | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023117590-A1 | SOLUTION ELECTROSPUN FIBERS, COMPOSITIONS COMPRISING THE SAME AND A PROCESS OF MANUFACTURING THEREOF | UNIVERSITEIT GENT (BE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4202036-A1 | METHODS AND COMPOSITIONS FOR STEM CELL TRANSPLANTATION | Angiocrine Bioscience, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| US-11685925-B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | SYNLOGIC OPERATING COMPANY, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| CN-116323949-A | Compositions and methods for treating ocular disorders | 方拓生物科技公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-3430400-B1 | DOSING REGIMENS FOR TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4196110-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | Board of Regents, The University of Texas System (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230181689-A1 | SINGLE DOSE METHODS FOR PREVENTING AND TREATING FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230172949-A1 | THERMO-KINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS | BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230167181-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURE USING THERMALLY CONDUCTIVE EXCIPIENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-01 | — | — | US | disclosed |
| CN-116162175-A | Influenza virus vaccine and application thereof | 西奈山伊坎医学院 | 2023-05-26 | — | — | CN | disclosed |
| US-20230158259-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS | TOPELIA AUST LIMITED (652 771 670) (AU) | 2023-05-25 | — | — | US | disclosed |
| WO-2023086832-A1 | METHODS OF PREPARING DOSAGE FORMS USING 3D PRINTING CONTAINING AMORPHOUS SOLID DISPERSIONS | BOARD OF REGENTS, THE UNIVERSITY OFTEXAS SYSTEM (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-4178626-A2 | UNIVERSAL CAR-NK CELL TARGETING VARIOUS EPITOPES OF HIV-1 GP160 | University of Southern California (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11649477-B2 | Assays and reagents for antimicrobial susceptibility testing | SeLux Diagnostics, Inc. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648210-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649215-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2023-05-16 | — | — | US | disclosed |
| US-11649215-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2023-05-16 | — | — | US | disclosed |
| US-11649215-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2023-05-16 | — | — | US | disclosed |
| US-11648209-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-05-16 | — | — | US | disclosed |
| CN-116077499-A | Anti-azole aspergillus fumigatus pharmaceutical composition and application thereof | 徐州医科大学 | 2023-05-09 | — | — | CN | disclosed |
| CN-116064571-A | Mango salt-tolerant gene and identification method and application thereof | 中国热带农业科学院三亚研究院 | 2023-05-05 | — | — | CN | disclosed |
| US-20230138752-A1 | PLASTICIZERS TO IMPROVE RELEASE PERFORMANCE OF AMORPHOUS SOLID DISPERSIONS | PURDUE RESEARCH FOUNDATION (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230137582-A1 | QUINOLONE DISPERSIONS | SOMERSET THERAPEUTICS, LLC | 2023-05-04 | — | — | US | disclosed |
| US-11638758-B2 | Itraconazole compositions and dosage forms, and methods of using the same | MAYNE PHARMA INTERNATIONAL PTY. LTD (AU) | 2023-05-02 | — | — | US | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| EP-4164618-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | Board of Regents, The University of Texas System (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4161627-A1 | METHODS FOR DELIVERING BIOACTIVE COMPOSITIONS AND FORMULATIONS TO THE SKIN USING MICROCHANNEL DELIVERY DEVICE | Aquavit Pharmaceuticals, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115955965-A | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | 拓比利亚欧斯特有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115944654-A | Methods and products for treating gastrointestinal disorders | 芬奇治疗控股有限责任公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20230095683-A1 | COPROCOCCUS BACTERIA FOR USE IN THE TREATMENT OF METABOLIC SYNDROME AND INFLAMMATORY BOWEL DISEASES | SORBONNE UNIVERSITE (FR) | 2023-03-30 | — | — | US | disclosed |
| EP-4153745-A1 | VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY | Boehringer Ingelheim International GmbH (DE) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153145-A1 | GRANULES FOR 3D PRINTING TECHNOLOGY | Board of Regents, The University of Texas System (US) | 2023-03-29 | — | — | EP | disclosed |
| CN-115843565-A | Method for improving plant performance | 以色列农业和农村发展部农业研究组织(范卡尼中心) | 2023-03-28 | — | — | CN | disclosed |
| WO-2023044316-A1 | DIAGNOSIS AND TREATMENT OF HISTOPLASMOSIS | THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-11596657-B2 | Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2023-03-07 | — | — | US | disclosed |
| EP-4138832-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS | Topelia Aust Limited (AU) | 2023-03-01 | — | — | EP | disclosed |
| US-11590085-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230052945-A1 | Thermally Gelling Drug Formulations | UNM RAINFOREST INNOVATIONS (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230039551-A1 | BUFFER- AND CHELATOR-FREE, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | SOMERSET THERAPEUTICS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-20230040283-A1 | ENHANCED DELIVERY OF IMMUNOSUPPRESSIVE DRUG COMPOSITIONS FOR PULMONARY DELIVERY | UNIV TEXAS (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230042072-A1 | BUFFER-FREE, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | SOMERSET THERAPEUTICS, LLC | 2023-02-09 | — | — | US | disclosed |
| WO-2023010170-A1 | STABILISED COMPOSITIONS | Rumin8 Pty Ltd (AU) | 2023-02-09 | — | — | WO | disclosed |
| US-20230040977-A1 | CHELATED, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | SOMERSET THERAPEUTICS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-20230040719-A1 | Pharmaceutical Formulation with Improved Solubility and Bioavailability | BIONANOPHARMA S.L. (ES) | 2023-02-09 | — | — | US | disclosed |
| US-20230044398-A1 | TREATMENT OF OPHTHALMOLOGICAL CONDITIONS USING BUFFER-FREE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE | SOMERSET THERAPEUTICS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-20230043588-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | SYNLOGIC OPERATING COMPANY, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11571464-B2 | C-type natriuretic peptide agent for the treatment of alopecia | IGISU CO., LTD. (JP) | 2023-02-07 | — | — | US | disclosed |
| CN-115684447-A | Method and apparatus for quantifying target ion species | 布鲁克·道尔顿有限及两合公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023007514-A1 | IMPROVED ORAL BIOAVAILABLE PHARMACEUTICAL COMPOSITIONS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2023-02-02 | — | — | WO | disclosed |
| US-20230026843-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230028227-A1 | METHOD AND DEVICE FOR THE QUANTIFICATION OF TARGET ION SPECIES | BRUKER DALTONICS GMBH & CO KG (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230026943-A1 | BUFFER-FREE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | SOMERSET THERAPEUTICS, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-4114420-A1 | COPROCOCCUS BACTERIA FOR USE IN THE TREATMENT OF METABOLIC SYNDROME AND INFLAMMATORY BOWEL DISEASES | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (FR) | 2023-01-11 | — | — | EP | disclosed |
| US-20230001396-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY AND PROTECTION OF THERAPEUTIC AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220401579-A1 | INCLUSION COMPLEXES OF PHARMACEUTICALS AND CYCLIC OLIGOMERS | DISPERSOL TECHNOLOGIES, LLC (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220401579-A1 | INCLUSION COMPLEXES OF PHARMACEUTICALS AND CYCLIC OLIGOMERS | DISPERSOL TECHNOLOGIES, LLC (US) | 2022-12-22 | — | — | US | disclosed |
| EP-3325612-B1 | METHODS AND COMPOSITIONS FOR STEM CELL TRANSPLANTATION | ANGIOCRINE BIOSCIENCE INC (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115463218-A | Shh channel regulation and control of biological rhythm and related application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-12-13 | — | — | CN | disclosed |
| US-11523987-B2 | Trimcinolone and moxifloxacin methods | SOMERSET THERAPEUTICS, LLC (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220387337-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220378752-A1 | NOVEL THERAPEUTIC AGENT FOR PROTOTHECA DISEASE | SEREN PHARMACEUTICALS INC. (JP) | 2022-12-01 | — | — | US | disclosed |
| US-20220378704-A1 | PROCESS FOR THE PREPARATION OF A NANOPARTICULATE ACTIVE INGREDIENT | BAYER AG (DE) | 2022-12-01 | — | — | US | disclosed |
| US-11510930-B2 | Gatifloxacin, prednisolone, and bromfenac compositions and methods | SOMERSET THERAPEUTICS, LLC (US) | 2022-11-29 | — | — | US | disclosed |
| US-11510880-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-29 | — | — | US | disclosed |
| CN-115381776-A | External spray containing itraconazole and eucalyptol and preparation method thereof | 南京朗博特动物药业有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115381797-A | Preparation and application of itraconazole sustained-release microspheres | 江南大学 | 2022-11-25 | — | — | CN | disclosed |
| US-20220354778-A1 | COMPOSITIONS AND METHODS OF MAKING BRITTLE-MATRIX PARTICLES THROUGH BLISTER PACK FREEZING | UNIV TEXAS (US) | 2022-11-10 | — | — | US | disclosed |
| CN-114996977-B | Water pollution restoration simulation method and system based on hydrodynamic coupling water quality model | 浙江远算科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-11484538-B2 | Bromfenac, prednisolone, and moxifloxacin compositions and methods | SOMERSET THERAPEUTICS, LLC (US) | 2022-11-01 | — | — | US | disclosed |
| US-11485730-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-11-01 | — | — | US | disclosed |
| US-11484501-B2 | Mechanochemical activated dry amorphisation by milling equilibrium between ap mesoporous silica | GRACE GMBH (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220340551-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2022-10-27 | — | — | US | disclosed |
| US-11478424-B2 | Mechanochemcial activated dry amorphisation by milling equilibrium between AP mesoporous silica | GRACE GMBH (US) | 2022-10-25 | — | — | US | disclosed |
| CN-115219611-A | Kit for determining 7 antifungal drugs in serum by ultra-high performance liquid chromatography-tandem mass spectrometry and application thereof | 上海义准生物有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-115219611-A | Kit for determining 7 antifungal drugs in serum by ultra-high performance liquid chromatography-tandem mass spectrometry and application thereof | 上海义准生物有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220331268-A1 | TREATMENT OF SKIN DISORDERS WITH TOPICAL COMBINATION COMPOSITIONS COMPRISING TAPINAROF AND AN ADDITIONAL AHR ACTIVATOR | SOL-GEL TECHNOLOGIES LTD. (IL) | 2022-10-20 | — | — | US | disclosed |
| WO-2022221177-A1 | DIAGNOSIS AND TREATMENT OF CONGESTIVE COLON FAILURE (CCF) | KHURANA VIKAS (US) | 2022-10-20 | — | — | WO | disclosed |
| US-11471403-B2 | Limited particle size triamcinolone and moxifloxacin compositions and associated methods of use | SOMERSET THERAPEUTICS, LLC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220324849-A1 | TRUNCATED ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2022-10-13 | — | — | US | disclosed |
| US-11465973-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2022-10-11 | — | — | US | disclosed |
| US-11465973-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2022-10-11 | — | — | US | disclosed |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2022-10-11 | — | — | US | disclosed |
| US-11464736-B2 | Thermally gelling drug formulations | UNM RAINFOREST INNOVATIONS (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220313611-A1 | METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-06 | — | — | US | disclosed |
| WO-2022207775-A1 | PROCESS FOR CONTINUOUS HOT MELT GRANULATION OF LOW SOLUBLE PHARMACEUTICALS | MERCK PATENT GMBH (DE) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022204286-A1 | COMPOSITIONS AND METHODS FOR TARGETED SYSTEMIC DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204043-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204219-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220304936-A1 | DRUG-POLYMER AMORPHOUS SOLID DISPERSIONS USING LINEAR POLY(ACRYLIC ACID) POLYMERS | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| EP-4062941-A1 | PROTEIN BASED EXCIPIENT FOR ACTIVE PHARMACEUTICAL INGREDIENTS | Rousselot B.V. (NL) | 2022-09-28 | — | — | EP | disclosed |
| CN-111588691-B | Itraconazole in-situ liquid crystal gel preparation for treating vaginitis and preparation method thereof | 安徽中医药大学 | 2022-09-23 | — | — | CN | disclosed |
| EP-4058190-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY AND PROTECTION OF THERAPEUTIC AGENTS | Board of Regents, The University of Texas System (US) | 2022-09-21 | — | — | EP | disclosed |
| US-11446242-B2 | Suspension component-specific triamcinolone and moxifloxacin compositions and associated methods of use | SOMERSET THERAPEUTICS, LLC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022192729-A1 | METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | WO | disclosed |
| US-11439591-B2 | Moxifloxacin and triamcinolone compositions and associated methods | SOMERSET THERAPEUTICS, LLC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11439650-B2 | Thermo-kinetic mixing for pharmaceutical applications | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-13 | — | — | US | disclosed |
| CN-114996977-A | Water pollution restoration simulation method and system based on hydrodynamic coupling water quality model | 浙江远算科技有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-113384570-B | Application of caffeic acid methyl ester and triazole composition in preparation of antifungal products | 山东省妇幼保健院 | 2022-08-26 | — | — | CN | disclosed |
| US-20220265833-A1 | ASPARTIC PROTEASE-TRIGGERED ANTIFUNGAL HYDROGELS | BROWN UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| WO-2022177993-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | VACCITECH NORTH AMERICA, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20220257673-A1 | METHODS AND PRODUCTS FOR TREATMENT OF GASTROINTESTINAL DISORDERS | FINCH THERAPEUTICS HOLDINGS LLC | 2022-08-18 | — | — | US | disclosed |
| US-20220259653-A1 | Dimer avoided multiplex polymerase chain reaction for amplification of multiple targets | iRepertoire, Inc. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-4041203-A1 | PROCESS FOR THE PREPARATION OF A NANOPARTICULATE ACTIVE INGREDIENT | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | disclosed |
| US-20220233460-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-28 | — | — | US | disclosed |
| US-20220226395-A1 | BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES | SYNLOGIC OPERATING COMPANY, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11390613-B2 | Azole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220220079-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-14 | — | — | US | disclosed |
| US-20220220079-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-14 | — | — | US | disclosed |
| EP-3454944-B1 | VOLATILE METABOLITE PROFILES FOR THE DIAGNOSIS AND TREATMENT OF MUCORALES FUNGI | BRIGHAM & WOMENS HOSPITAL INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11382910-B2 | Loteprednol and moxifloxacin compositions and methods | SOMERSET THERAPEUTICS, LLC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11384359-B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | SYNLOGIC OPERATING COMPANY, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11382899-B2 | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220213073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-07 | — | — | US | disclosed |
| US-20220213073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-07 | — | — | US | disclosed |
| US-20220213043-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-07 | — | — | US | disclosed |
| WO-2022147318-A1 | METHODS OF TREATMENT | ARENA PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-4021416-A1 | DRUG-POLYMER AMORPHOUS SOLID DISPERSIONS USING LINEAR POLY (ACRYLIC ACID) POLYMERS | Lubrizol Advanced Materials, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-4017524-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | Standard of Care Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114668849-A | Shh channel regulation and control of biological rhythm and related application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-06-28 | — | — | CN | disclosed |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| CN-114660200-A | Method for simultaneously measuring 4 triazole antifungal drugs in blood plasma by high performance liquid chromatography tandem mass spectrometry technology | 中国人民解放军总医院 | 2022-06-24 | — | — | CN | disclosed |
| WO-2022128918-A1 | DIAGNOSTIC METHOD FOR CANCER EVOLUTION PREDICTION, AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129661-A1 | AMPHOTERICIN B FORMULATIONS FOR INHALATION BASED ON COLLAPSED MICROPARTICLES CONTAINING CARBOHYDRATES AND AMINO ACIDS | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2022-06-23 | — | — | WO | disclosed |
| US-11364197-B2 | Compositions and methods of making brittle-matrix particles through blister pack freezing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022125869-A1 | COMPOSITIONS AND METHODS OF MAKING COCRYSTALS USING DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220183967-A1 | LIMITED PARTICLE SIZE TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS AND ASSOCIATED METHODS OF USE | SOMERSET THERAPEUTICS, LLC | 2022-06-16 | — | — | US | disclosed |
| US-20220183968-A1 | SUSPENSION COMPONENT-SPECIFIC TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS AND ASSOCIATED METHODS OF USE | SOMERSET THERAPEUTICS, LLC | 2022-06-16 | — | — | US | disclosed |
| US-20220183966-A1 | MOXIFLOXACIN AND TRIAMCINOLONE COMPOSITIONS AND ASSOCIATED METHODS | SOMERSET THERAPEUTICS, LLC | 2022-06-16 | — | — | US | disclosed |
| EP-4008314-A2 | THERMO-KINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS | Board of Regents, The University of Texas System (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-4005600-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | Yale University (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3448435-B1 | PROTEIN BASED EXCIPIENT FOR ACTIVE PHARMACEUTICAL INGREDIENTS | ROUSSELOT B V (NL) | 2022-06-01 | — | — | EP | disclosed |
| US-11339418-B2 | Antimicrobial susceptibility testing and microbial identification | SeLux Diagnostics, Inc. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3998109-A1 | NOVEL THERAPEUTIC AGENT FOR PROTOTHECA DISEASE | Seren Pharmaceuticals Inc. (JP) | 2022-05-18 | — | — | EP | disclosed |
| CN-114502182-A | Methods and products for treating gastrointestinal disorders | 芬奇治疗控股有限责任公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220142987-A1 | ANTI-FUNGAL AGENT | SEREN PHARMACEUTICALS INC. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220143143-A1 | USE OF ACTIVATORS OF THE ARYL HYDROCARBON RECEPTOR FOR TREATING GLUTEN-INDUCED GASTROINTESTINAL DISEASES | UNIV MCMASTER (CA) | 2022-05-12 | — | — | US | disclosed |
| US-20220133638-A1 | METHOD FOR PRODUCING NANOPARTICLES | LEON-NANODRUGS GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
| WO-2022094174-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESOPHAGEAL CONDITIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022090296-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR ENHANCING SOLUBILITY OF POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | MERCK PATENT GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022090297-A1 | METHOD FOR PRODUCING AN AMORPHOUS SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION FOR STABILIZING ACTIVE PHARMACEUTICAL INGREDIENTS | MERCK PATENT GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022090295-A1 | METHOD FOR PRODUCING AN AMORPHOUS SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION FOR STABILIZING ACTIVE PHARMACEUTICAL INGREDIENTS | MERCK PATENT GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| US-20220133637-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3990679-A1 | APPARATUS FOR FORMING A PLURALITY OF COATED PARTICLES, METHOD FOR FORMING A PLURALITY OF COATED PARTICLES, COATED PARTICLES | Nanexa AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3988107-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | Synlogic Operating Company, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11312707-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-04-26 | — | — | US | disclosed |
| US-11312707-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-04-26 | — | — | US | disclosed |
| US-11304911-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3980023-A1 | LIPID NANOPARTICLES CONTAINING PHARMACEUTICAL AND/OR NUTRACEUTICAL AGENTS AND METHODS THEREOF | Board of Regents, The University of Texas System (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11298315-B2 | Triamcinolone and moxifloxacin compositions | SOMERSET THERAPEUTICS, LLC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-114302710-A | Drug-polymer amorphous solid dispersions using linear poly (acrylic acid) polymers | 路博润先进材料公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20220105100-A1 | SAFE BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT | SOMERSET THERAPEUTICS, LLC | 2022-04-07 | — | — | US | disclosed |
| US-20220105103-A1 | SAFE USE OF BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT | SOMERSET THERAPEUTICS, LLC | 2022-04-07 | — | — | US | disclosed |
| US-20220105102-A1 | METHODS OF EFFICIENTLY REDUCING INTRAOCULAR PRESSURE | SOMERSET THERAPEUTICS, LLC | 2022-04-07 | — | — | US | disclosed |
| US-20220106302-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2022-04-07 | — | — | US | disclosed |
| US-20220105101-A1 | EFFICIENT BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS | SOMERSET THERAPEUTICS, LLC | 2022-04-07 | — | — | US | disclosed |
| EP-3978499-A1 | PHOTOPROTECTIVE COMPOSITIONS CONTAINING MALASSEZIA-DERIVED COMPOUNDS AND/OR CHEMICAL ANALOGS THEREOF | VERSICOLOR TECHNOLOGIES, LLC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11291693-B2 | Bacteria engineered to treat metabolic diseases | SYNLOGIC OPERATING COMPANY, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220089579-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220088030-A1 | METHODS FOR TREATMENT OF DISEASES | BIOSSIL INC. (CA) | 2022-03-24 | — | — | US | disclosed |
| US-20220088036-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS | CORCEPT THERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220088036-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS | CORCEPT THERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-11279936-B2 | Aptamers, biosensors and detection methods for common azole-class antifungal drugs | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220072136-A1 | PROTEIN BASED EXCIPIENT FOR ACTIVE PHARMACEUTICAL INGREDIENTS | DISPERSOME IP APS (NL) | 2022-03-10 | — | — | US | disclosed |
| US-20220062303-A1 | PREDNISOLONE AND MOXIFLOXACIN COMPOSITIONS AND METHODS | SOMERSET THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20220062271-A1 | LOTEPREDNOL AND MOXIFLOXACIN COMPOSITIONS AND METHODS | SOMERSET THERAPEUTICS, LLC (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220062301-A1 | BROMFENAC, PREDNISOLONE, AND MOXIFLOXACIN COMPOSITIONS AND METHODS | SOMERSET THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20220064600-A1 | METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF | CELLERANT THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220062167-A1 | TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS | SOMERSET THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20220062302-A1 | GATIFLOXACIN, PREDNISOLONE, AND BROMFENAC COMPOSITIONS AND METHODS | SOMERSET THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20220062168-A1 | TRIMCINOLONE AND MOXIFLOXACIN METHODS | SOMERSET THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
| CN-114126609-A | Novel therapeutic agent for prototheca disease | 株式会社赛轮制药 | 2022-03-01 | — | — | CN | disclosed |
| US-20220054715-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | UNIV EMORY (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3957639-A1 | PHOTOPROTECTIVE COMPOSITIONS CONTAINING MALASSEZIA-DERIVED COMPOUNDS AND/OR CHEMICAL ANALOGS THEREOF | Einziger, Michael (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2022036290-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3954370-A1 | ANTI-FUNGAL AGENT | Seren Pharmaceuticals Inc. (JP) | 2022-02-16 | — | — | EP | disclosed |
| US-20220023202-A1 | Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same | MARTIN MICHAEL LEE (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2022016216-A1 | BIOCOMPATIBLE POLYMER COMPOSITIONS | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2022-01-27 | — | — | WO | disclosed |
| US-11225463-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2022-01-18 | — | — | US | disclosed |
| US-11220493-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-01-11 | — | — | US | disclosed |
| US-11220493-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-01-11 | — | — | US | disclosed |
| US-11185548-B2 | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases | HELMHOLTZ ZENTRUM MUNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2021-11-30 | — | — | US | disclosed |
| US-11179501-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| US-11028078-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2021108022-A1 | INCLUSION COMPLEXES OF PHARMACEUTICALS AND CYCLIC OLIGOMERS | DISPERSOL TECHNOLOGIES, LLC (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210053950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-02-25 | — | — | US | disclosed |
| US-20210053950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-02-25 | — | — | US | disclosed |
| US-20200383975-A1 | TOPICAL FORMULATIONS FOR DELIVERY OF HEDGEHOG INHIBITOR COMPOUNDS AND USE THEREOF | PellePharm, Inc. | 2020-12-10 | — | — | US | disclosed |
| US-20200361912-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2020-11-19 | — | — | US | disclosed |
| US-20200361912-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2020-11-19 | — | — | US | disclosed |
| US-20200361874-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2020-11-19 | — | — | US | disclosed |
| EP-2803357-B1 | Angiogenesis inhibitors | UNIV JOHNS HOPKINS (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10695344-B2 | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof | PellePharm, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3099679-B1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | UNIV CONNECTICUT (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200072711-A1 | FLUORESCENT ENDOPLASMIC RETICULUM TRACKERS FOR LIVE CELL IMAGING OF PATHOGENIC YEAST | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2020-03-05 | — | — | US | disclosed |
| EP-3581566-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2019-12-18 | — | — | EP | disclosed |
| EP-3581566-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2019-12-18 | — | — | EP | disclosed |
| US-10369147-B2 | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof | PellePharm, Inc. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190224378-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | UNIV EMORY (US) | 2019-07-25 | — | — | US | disclosed |
| US-10286113-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190134027-A1 | TOPICAL FORMULATIONS FOR DELIVERY OF HEDGEHOG INHIBITOR COMPOUNDS AND USE THEREOF | PellePharm, Inc. | 2019-05-09 | — | — | US | disclosed |
| US-20190040046-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-07 | — | — | US | disclosed |
| WO-2018115319-A2 | INHIBITORS OF CYTOCHROME P450 FAMILY 7 SUBFAMILY B MEMBER 1 (CYP7B1) FOR USE IN TREATING DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018096497-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018096405-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2018-05-31 | — | — | WO | disclosed |
| US-9981956-B2 | Small molecule inhibitors of fibrosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981956-B2 | Small molecule inhibitors of fibrosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9839636-B2 | Itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839636-B2 | Itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839636-B2 | Itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170217943-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-08-03 | — | — | US | disclosed |
| US-20170217943-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-08-03 | — | — | US | disclosed |
| US-20170209436-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-27 | — | — | US | disclosed |
| US-20170209436-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-27 | — | — | US | disclosed |
| US-20170209436-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-27 | — | — | US | disclosed |
| US-9650365-B2 | Itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650365-B2 | Itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650365-B2 | Itraconazole analogues and methods of use thereof | UNIVERSITY OF CONNECTICUT (US) | 2017-05-16 | — | — | US | disclosed |
| US-9642865-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642806-B2 | Antifungal compositions with improved bioavailability | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-20160361470-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | UNIV EMORY (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160354368-A1 | TOPICAL FORMULATIONS FOR DELIVERY OF HEDGEHOG INHIBITOR COMPOUNDS AND USE THEREOF | SOL-GEL TECHNOLOGIES LTD. (IL) | 2016-12-08 | — | — | US | disclosed |
| WO-2016196928-A1 | TOPICAL FORMULATIONS FOR DELIVERY OF HEDGEHOG INHIBITOR COMPOUNDS AND USE THEREOF | PellePharm, Inc. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160354368-A1 | TOPICAL FORMULATIONS FOR DELIVERY OF HEDGEHOG INHIBITOR COMPOUNDS AND USE THEREOF | SOL-GEL TECHNOLOGIES LTD. (IL) | 2016-12-08 | — | — | US | disclosed |
| US-20160340346-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| US-20160340346-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| US-20160340346-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| US-20160264556-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | UNIV JOHNS HOPKINS (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264556-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | UNIV JOHNS HOPKINS (US) | 2016-09-15 | — | — | US | disclosed |
| EP-2181330-B2 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2016-08-31 | — | — | EP | disclosed |
| US-20160151503-A1 | COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY-WATER SOLUBLE DRUGS | MW ENCAP LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160151503-A1 | COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY-WATER SOLUBLE DRUGS | MW ENCAP LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-9346791-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346791-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| EP-1912625-B1 | ITRACONAZOLE COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | ABBVIE DEUTSCHLAND (DE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2015116947-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2015-08-06 | — | — | WO | disclosed |
| US-9095589-B2 | Chirally pure isomers of itraconazole for use as angiogenesis inhibitors | JOHNS HOPKINS UNIVERSITY (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095589-B2 | Chirally pure isomers of itraconazole for use as angiogenesis inhibitors | JOHNS HOPKINS UNIVERSITY (US) | 2015-08-04 | — | — | US | disclosed |
| US-8980930-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | UNIV JOHNS HOPKINS (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2803357-A2 | Angiogenesis inhibitors | THE JOHNS-HOPKINS UNIVERSITY (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140248372-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140221393-A1 | Itraconazole Analogs and Use Thereof | THE JOHNS HOPKINS UNIVERSITY | 2014-08-07 | — | — | US | disclosed |
| US-20140221393-A1 | Itraconazole Analogs and Use Thereof | THE JOHNS HOPKINS UNIVERSITY | 2014-08-07 | — | — | US | disclosed |
| US-20140134244-A1 | ANTIFUNGAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-05-15 | — | — | US | disclosed |
| US-8653083-B2 | Hedgehog pathway antagonists to treat disease | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-02-18 | — | — | US | disclosed |
| US-8591948-B2 | Antifungal compositions with improved bioavailability | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-26 | — | — | US | disclosed |
| EP-2181330-B1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2013-11-20 | — | — | EP | disclosed |
| US-8486456-B2 | Itraconazole compositions with improved bioavailability | ABBOTT GMBH & CO., KG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102614-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE FOR USE AS ANGIOGENESIS INHIBITORS | JOHNS HOPKINS UNIVERSITY | 2013-04-25 | — | — | US | disclosed |
| US-20130102614-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE FOR USE AS ANGIOGENESIS INHIBITORS | JOHNS HOPKINS UNIVERSITY | 2013-04-25 | — | — | US | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| EP-1919480-B1 | HEDGEHOG PATHWAY ANTAGONISTS TO TREAT DISEASE | UNIV JOHNS HOPKINS (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2517686-A2 | A kit comprising a multi-chamber container | Combino Pharm, S.L. (ES) | 2012-10-31 | — | — | EP | disclosed |
| EP-2431477-A1 | POLYKETIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059038-A1 | POLYKETIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059038-A1 | POLYKETIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INC. | 2012-02-23 | — | — | US | disclosed |
| EP-2404602-A1 | Hedgehog pathway antagonists to treat cancer | The Johns Hopkins University (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110262517-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE AND INHIBITORS OF LANOSTEROL 14A-DEMETHYLASE FOR USE AS ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262517-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE AND INHIBITORS OF LANOSTEROL 14A-DEMETHYLASE FOR USE AS ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2316468-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2266590-A2 | Active agent delivery sytems and methods for protecting and administering active agents | Shire LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100143455-A1 | Triazole antifungal agents | WU NIAN | 2010-06-10 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090214656-A1 | ITRACONAZOLE COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | ABBOTT GMBH & CO. KG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090203713-A1 | Hedgehog pathway antagonists to treat disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| US-20090088443-A1 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | REMENAR JULIUS | 2009-04-02 | — | — | US | disclosed |
| EP-1511490-A4 | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | TRANSFORM PHARMACEUTICALS INC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080305173-A1 | AMORPHOUS DRUG BEADS | BOGUE BEUFORD ARLIE | 2008-12-11 | — | — | US | disclosed |
| US-7459561-B2 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2008-12-02 | — | — | US | disclosed |
| US-20080287299-A1 | Use of Imidazole and/or Triazole Derivatives for Combating Plant Pests; as Well as Method for Controlling Diseases/Insects/Mites/Nematodes and Weeds, Particularly Foliar and/or Soil Diseases | FMC QUIMICA DO BRASIL LTDA (BR) | 2008-11-20 | — | — | US | disclosed |
| US-7446107-B2 | Crystalline forms of conazoles and methods of making and using the same | TRANSFORM PHARMACEUTICALS, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080193499-A1 | Angiogenesis Inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008088776-A2 | AMORPHOUS DRUG BEADS | CAPRICORN PHARMA INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1718640-A4 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | TRANSFORM PHARMACEUTICALS INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070293674-A1 | Novel Saperconazole Crystalline Forms and Related Processes, Pharmaceutical Compositions and Methods | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070148240-A1 | Oral formulation containing itraconazole and methods for manufacturing and using the same | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 2007-06-28 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| EP-1742941-A1 | NOVEL SAPERCONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | Transform Pharmaceuticals, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-7163700-B2 | Amorphous drug beads | CAPRICORN PHARMA, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-7151182-B2 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2006-12-19 | — | — | US | disclosed |
| US-20060263436-A1 | Antifungal compositions with improved bioavailability | BAERT LIEVEN E C | 2006-11-23 | — | — | US | disclosed |
| EP-1718640-A1 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | Transform Pharmaceuticals, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1490090-A4 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PHARMACEUTICALS INC (US) | 2006-09-20 | — | — | EP | disclosed |
| US-7081255-B2 | Antifungal compositions with improved bioavailability | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-07-25 | — | — | US | disclosed |
| US-7078526-B2 | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods | TRANSFORM PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-7060708-B2 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060062848-A1 | Formulation comprising itraconazole | NEKTAR THERAPEUTICS UK LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| WO-2005118577-A1 | NOVEL SAPERCONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050226932-A1 | Pharmaceutical formulations for itraconazole | SAMYANG CORPORATION | 2005-10-13 | — | — | US | disclosed |
| US-20050226924-A1 | Composition comprising itraconazole for oral administration | CHI, SANG-CHEOL (KR) | 2005-10-13 | — | — | US | disclosed |
| WO-2005092884-A1 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | TRANSFORM PHARMACEUTICALS, INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| EP-1104291-B1 | PELLETS HAVING A CORE COATED WITH AN ANTIFUNGAL AND A POLYMER | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005060361-A2 | PHARMACEUTICAL FORMULATIONS FOR ITRACONAZOLE | SAMYANG CORPORATION (KR) | 2005-07-07 | — | — | WO | disclosed |
| US-20050074494-A1 | Itraconazole immediate release formulation | ANDRX LABS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050070551-A1 | Novel crystalline forms of conazoles and methods of making and using the same | TRANSFORM PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| EP-1280795-B1 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| EP-1511490-A2 | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | Transform Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20050038075-A1 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | disclosed |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | disclosed |
| EP-1490090-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | New River Pharmaceuticals Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004108114-A2 | ANTI-FUNGAL COMPOSITION AND A PROCESS FOR ITS MANUFACTURE | PATEL DINESH SHANTILAL (IN) | 2004-12-16 | — | — | WO | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
| US-20040115266-A1 | Oral itraconazole formulations and methods of making the same | STIEFEL LABORATORIES, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1032263-B1 | SURFACTANT-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS FOR USING SAME | WOODWARD LAB INC (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6737082-B1 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method | LICONSA LIBERACION CONTROLADA DE SUSTANCIAS ACTIVAS, S.A. (ES) | 2004-05-18 | — | — | US | disclosed |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040019211-A1 | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | US | disclosed |
| US-6673373-B2 | FOR AN AZOLE ANTIFUNGAL OR ANTIBACTERIAL DRUG; CORE AND A DRUG EMULSION LAYER CONTAINING THE DRUG, AN EMULSIFIER, BINDER AND ABSORBENT AID SUCH AS CITRIC ACID; SOLUBILITY, BIOAVAILABILITY | CARLSBAD TECHNOLOGY INC. | 2004-01-06 | — | — | US | disclosed |
| US-6663901-B1 | Itraconazole; sugar core, a coating film of a water soluble polymer, a seal coating | JANSSEN PHARMACEUTICAL N.V. (BE) | 2003-12-16 | — | — | US | disclosed |
| US-6663897-B2 | Coating with water soluble polymer; fungicide | DSM IP ASSETS B.V. (NL) | 2003-12-16 | — | — | US | disclosed |
| WO-2003101392-A2 | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED PROCESSES, PHARMACEUTICAL COMPOSITIONS AND METHODS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-0904060-B1 | ANTIFUNGAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | JANSSEN PHARMACEUTICA NV (BE) | 2003-12-10 | — | — | EP | disclosed |
| EP-1350508-A1 | Antifungal formulation and the methods for manufacturing and using the same | Yung Shin Pharm. Ind. Co. Ltd. (TW) | 2003-10-08 | — | — | EP | disclosed |
| WO-2003079972-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PARMACEUTICALS INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| EP-0969821-B1 | PELLETS HAVING A CORE COATED WITH AN ANTIFUNGAL AND A POLYMER | JANSSEN PHARMACEUTICA NV (BE) | 2003-06-04 | — | — | EP | disclosed |
| US-20030082239-A1 | Antifungal compositions with improved bioavailability | JANSSEN PHARMACEUTICAL, N.V. | 2003-05-01 | — | — | US | disclosed |
| EP-1103252-B1 | PHARMACEUTICAL ORAL PREPARATION OF A COMPOUND HAVING AN ANTIFUNGIC ACTIVITY, AND PREPARATION METHOD | LICONSA LIBERACION CONTROLADA (ES) | 2003-03-12 | — | — | EP | disclosed |
| US-20030026843-A1 | Amorphous drug beads | CAPRICORN PHARMA INC. | 2003-02-06 | — | — | US | disclosed |
| EP-1280795-A2 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| US-20020176894-A1 | Antifungal formulation and the methods for manufacturing and using the same | CARLSBAD TECHNOLOGY, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020150620-A1 | Oral itraconazole formulations and methods of making the same | STIEFEL LABORATORIES, INC. | 2002-10-17 | — | — | US | disclosed |
| EP-1039909-B1 | METHOD OF PRODUCTION AND COMPOSITION OF AN ORAL PREPARATION OF ITRACONAZOLE | CHOONGWAE PHARMA CORP (KR) | 2002-10-09 | — | — | EP | disclosed |
| US-6455530-B1 | FUNGICIDES | SEPRACOR INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1143950-A3 | TOPICAL APPLICATION PRODUCTS | IPR-Institute for Pharmaceutical Research AG (CH) | 2002-05-15 | — | — | EP | disclosed |
| EP-0721337-B1 | ORAL FORMULATIONS OF AN ANTIFUNGAL | JANSSEN PHARMACEUTICA NV (BE) | 2001-12-05 | — | — | EP | disclosed |
| EP-1143950-A2 | TOPICAL APPLICATION PRODUCTS | IPR-Institute for Pharmaceutical Research AG (CH) | 2001-10-17 | — | — | EP | disclosed |
| US-20010007678-A1 | ANTIFUNGAL COMPOSITIONS WITH IPMROVED BIOAVAILABILITY | JANSSEN PHARMACEUTICA, N.V. (BE) | 2001-07-12 | — | — | US | disclosed |
| EP-1103252-A1 | PHARMACEUTICAL ORAL PREPARATION OF A COMPOUND HAVING AN ANTIFUNGIC ACTIVITY, AND PREPARATION METHOD | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. (ES) | 2001-05-30 | — | — | EP | disclosed |
| EP-0631578-B1 | ITRACONAZOLE AND SAPERCONAZOLE STEREOISOMERS | JANSSEN PHARMACEUTICA NV (BE) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001032652-A2 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2001-05-10 | — | — | WO | disclosed |
| US-6166018-A | 2R, 4S, R, S- and 2S, 4R, R, S-hydroxyitraconazole | SEPRACOR INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6147077-A | FUNGICIDE | SEPRACOR INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-2000015202-A2 | TOPICAL APPLICATION PRODUCTS | IPR-INSTITUTE FOR PHARMACEUTICAL RESEARCH AG (CH) | 2000-03-23 | — | — | WO | disclosed |
| EP-0938487-A2 | 2$i(R),4$i(S),$i(R),$i(S)- AND 2$i(S),4$i(R),$i(R),$i(S)-HYDROXYITRACONAZOLE- AND HYDROXYSAPERCONAZOLE DERIVATIVES | SEPRACOR, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| EP-0712575-B1 | Synergistic insecticidal compositions | ROHM & HAAS (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0759741-B1 | MUCOADHESIVE EMULSIONS CONTAINING CYCLODEXTRIN | JANSSEN PHARMACEUTICA NV (BE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998021213-A2 | 2R,4S,R,S- AND 2S,4R,R,S-HYDROXYITRACONAZOLE- AND HYDROXYSAPERCONAZOLE DERIVATIVES | SEPRACOR, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| EP-0658103-B1 | BEADS HAVING A CORE COATED WITH AN ANTIFUNGAL AND A POLYMER | JANSSEN PHARMACEUTICA NV (BE) | 1996-11-20 | — | — | EP | disclosed |
| US-5571829-A | CYTOCHROME P450 ENZYME INHIBITOR AND AN N,N'-DIBENZOYL-N'-TERT-ALKYL-HYDRAZINE | ROHM AND HAAS COMPANY (US) | 1996-11-05 | — | — | US | disclosed |
| EP-0721337-A1 | ORAL FORMULATIONS OF AN ANTIFUNGAL | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-07-17 | — | — | EP | disclosed |
| EP-0712575-A1 | Synergistic insecticidal compositions | ROHM AND HAAS COMPANY (US) | 1996-05-22 | — | — | EP | disclosed |
| US-5474997-A | Administering (2R,4S)itraconazole, free of (2S,4R) stereoisomer, to reduce side effects | SEPRACOR, INC. (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995008993-A1 | ORAL FORMULATIONS OF AN ANTIFUNGAL | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-04-06 | — | — | WO | disclosed |
| EP-0499322-A1 | (Carboxyl)alkyloxyalkyl derivatives of cyclodextrins | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-19 | — | — | EP | disclosed |
| US-4916134-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACUETICA N.V. (BE) | 1990-04-10 | — | — | US | disclosed |
| US-4916134-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACUETICA N.V. (BE) | 1990-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390272-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | CYP3A4 4694/4885ABCG2 438/4885LMNA 350/4885 |
| US-20050070551-A1 | Novel crystalline forms of conazoles and methods of making and using the same | CYP51A1, CYP3A5, ERG28 | CYP3A4 10/4885ABCG2 115/4885LMNA 3498/4885 |
| US-12097210-B2 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | NR3C1, NR3C2, CYP3A5 | CYP3A4 21/4885ABCG2 409/4885LMNA 4861/4885 |
| US-20230039551-A1 | BUFFER- AND CHELATOR-FREE, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | UACA, CRYZ, MYOC | CYP3A4 3871/4885ABCG2 1127/4885LMNA 1303/4885 |
| US-20160340346-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | GLI1, SHH, SMO | CYP3A4 2373/4885ABCG2 995/4885LMNA 4777/4885 |
| US-11648209-B2 | Compositions and methods for organ specific delivery of nucleic acids | POLRMT, FABP1, SNRPE | CYP3A4 4622/4885ABCG2 2518/4885LMNA 185/4885 |
| US-20070293674-A1 | Novel Saperconazole Crystalline Forms and Related Processes, Pharmaceutical Compositions and Methods | CYP51A1, CYP3A5, CYP3A43 | CYP3A4 4/4885ABCG2 87/4885LMNA 3944/4885 |
| US-20240293351-A1 | METHODS OF ADMINISTERING SYNTHETIC TRITERPENOIDS | CYP4A11, CYP3A4, CYP11B1 | CYP3A4 2/4885ABCG2 131/4885LMNA 4341/4885 |
| US-20260066250-A1 | METHOD AND DEVICE FOR THE QUANTIFICATION OF TARGET ION SPECIES | SRMS, IAPP, PTMS | CYP3A4 4530/4885ABCG2 1800/4885LMNA 3696/4885 |
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | IAPP, BRCA1, ANXA11 | CYP3A4 4843/4885ABCG2 4620/4885LMNA 2200/4885 |
| US-11826373-B2 | Methods for treatment of diseases | SOD1, GLS, GLS2 | CYP3A4 4289/4885ABCG2 4096/4885LMNA 1540/4885 |
| US-20240269269-A1 | Self-Assembling Nanoparticles | UBE2B, CD4, UBE2G2 | CYP3A4 4019/4885ABCG2 3818/4885LMNA 3343/4885 |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | CYP3A4 2577/4885ABCG2 4831/4885LMNA 4490/4885 |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | CYP3A4 322/4885ABCG2 938/4885LMNA 4231/4885 |
| US-11766408-B2 | Compositions and methods for organ specific delivery of nucleic acids | POLRMT, FABP1, SNRPE | CYP3A4 4622/4885ABCG2 2518/4885LMNA 185/4885 |
| US-12102632-B2 | Quinolone dispersions | F12, CFD, NFKBIA | CYP3A4 531/4885ABCG2 240/4885LMNA 2333/4885 |
| US-11382910-B2 | Loteprednol and moxifloxacin compositions and methods | PROC, MLEC, LAGE3 | CYP3A4 1171/4885ABCG2 389/4885LMNA 1875/4885 |
| US-20220105100-A1 | SAFE BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT | ADRB2, ADRA2C, ADRB3 | CYP3A4 781/4885ABCG2 96/4885LMNA 1538/4885 |
| US-20220062303-A1 | PREDNISOLONE AND MOXIFLOXACIN COMPOSITIONS AND METHODS | SERPINA6, PF4, F12 | CYP3A4 567/4885ABCG2 1490/4885LMNA 3342/4885 |
| US-12029729-B2 | Chelated, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof | CRYZ, UACA, MYOC | CYP3A4 3562/4885ABCG2 1421/4885LMNA 2112/4885 |
| US-20230137582-A1 | QUINOLONE DISPERSIONS | NFKBIA, CFD, F12 | CYP3A4 438/4885ABCG2 305/4885LMNA 2780/4885 |
| US-20170217943-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | MMP1, COL2A1, MMP8 | CYP3A4 4660/4885ABCG2 3265/4885LMNA 2026/4885 |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | CYP3A4 4785/4885ABCG2 362/4885LMNA 760/4885 |
| US-20220220079-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES | SI, HBG1, HBG2 | CYP3A4 18/4885ABCG2 496/4885LMNA 1815/4885 |
| US-20230219936-A1 | PROCESS FOR THE PREPARATION SALTS OF TRIAZOLE COMPOUNDS | CYP51A1, CYP3A5, NUP155 | CYP3A4 59/4885ABCG2 95/4885LMNA 3092/4885 |
| US-20200383975-A1 | TOPICAL FORMULATIONS FOR DELIVERY OF HEDGEHOG INHIBITOR COMPOUNDS AND USE THEREOF | SHH, GLI1, SMO | CYP3A4 3813/4885ABCG2 1562/4885LMNA 3149/4885 |
| US-11649215-B2 | Compositions and methods for the treatment of oral infectious diseases | SI, HBG1, HBG2 | CYP3A4 18/4885ABCG2 496/4885LMNA 1815/4885 |
| US-20240156920-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | MMP1, MMP2, MMP8 | CYP3A4 237/4885ABCG2 3357/4885LMNA 3136/4885 |
| US-12203124-B2 | Methods for improved rapid antimicrobial susceptibility testing | AMPD3, AMPD1, AMPD2 | CYP3A4 1351/4885ABCG2 5/4885LMNA 3491/4885 |
| US-20190134027-A1 | TOPICAL FORMULATIONS FOR DELIVERY OF HEDGEHOG INHIBITOR COMPOUNDS AND USE THEREOF | SHH, GLI1, SMO | CYP3A4 3813/4885ABCG2 1562/4885LMNA 3149/4885 |
| US-11291693-B2 | Bacteria engineered to treat metabolic diseases | GOT2, BPGM, MLYCD | CYP3A4 1442/4885ABCG2 3393/4885LMNA 2724/4885 |
| US-20220062167-A1 | TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS | TTPA, F12, PROC | CYP3A4 1387/4885ABCG2 748/4885LMNA 3394/4885 |
| US-20120059038-A1 | POLYKETIDE COMPOUND | IL5, IL15, KAT5 | CYP3A4 3180/4885ABCG2 3668/4885LMNA 2712/4885 |
| US-20220062302-A1 | GATIFLOXACIN, PREDNISOLONE, AND BROMFENAC COMPOSITIONS AND METHODS | EYA3, PDE6G, PDE6C | CYP3A4 1984/4885ABCG2 284/4885LMNA 4427/4885 |
| US-10695344-B2 | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof | SHH, GLI1, SMO | CYP3A4 3813/4885ABCG2 1562/4885LMNA 3149/4885 |
| US-20230001396-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY AND PROTECTION OF THERAPEUTIC AGENTS | LITAF, MIF, MB | CYP3A4 4135/4885ABCG2 1933/4885LMNA 1893/4885 |
| US-12133924-B2 | Compositions and methods for organ specific delivery of nucleic acids | POLRMT, FABP1, SNRPE | CYP3A4 4622/4885ABCG2 2518/4885LMNA 185/4885 |
| US-11793789-B2 | Treatment of ophthalmological conditions using buffer-free ophthalmological compositions of ketorolac and phenylephrine | CRYZ, MYOC, KIF23 | CYP3A4 3580/4885ABCG2 2813/4885LMNA 1235/4885 |
| US-20160361470-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | BMP4, SOST, BMP2 | CYP3A4 3169/4885ABCG2 2693/4885LMNA 1749/4885 |
| US-11298315-B2 | Triamcinolone and moxifloxacin compositions | TTPA, F12, PROC | CYP3A4 1387/4885ABCG2 748/4885LMNA 3394/4885 |
| US-20250235422-A1 | DODECA-2,4,6,8,10-PENTAENOIC ACID COMPOSITIONS AND USES THEREOF | CUTA, ALOX5AP, DAGLA | CYP3A4 3166/4885ABCG2 3812/4885LMNA 3476/4885 |
| US-11485730-B2 | Compositions and methods for the treatment of fungal infections | SI, CYP3A7, ERG28 | CYP3A4 4/4885ABCG2 279/4885LMNA 2173/4885 |
| US-11185548-B2 | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases | CYP7A1, CYP7B1, CYP27A1 | CYP3A4 45/4885ABCG2 717/4885LMNA 3698/4885 |
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | CYP3A4 4792/4885ABCG2 3262/4885LMNA 3841/4885 |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | CYP3A4 379/4885ABCG2 728/4885LMNA 4206/4885 |
| US-20240374512-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | CYP3A4 4694/4885ABCG2 438/4885LMNA 350/4885 |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | CYP3A4 41/4885ABCG2 581/4885LMNA 2625/4885 |
| US-12527789-B2 | Inhibition of a tripartite VOR protein complex in multicellular organisms | VAPB, VAPA, OSBPL3 | CYP3A4 4217/4885ABCG2 3110/4885LMNA 4674/4885 |
| US-20090088443-A1 | NOVEL CRYSTALLINE FORMS OF CONAZOLES AND METHODS OF MAKING AND USING THE SAME | CYP51A1, CYP3A5, ERG28 | CYP3A4 10/4885ABCG2 115/4885LMNA 3498/4885 |
| US-20230302138-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | CYP3A4 4694/4885ABCG2 438/4885LMNA 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.